Oxford Biomedica (LON:OXB) Share Price Passes Above 200 Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 664.76 and traded as high as GBX 666. Oxford Biomedica shares last traded at GBX 659, with a volume of 359,950 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OXB. Deutsche Bank Aktiengesellschaft boosted their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a report on Friday, January 9th. Jefferies Financial Group began coverage on Oxford Biomedica in a report on Monday, March 23rd. They issued a “buy” rating and a GBX 827 price target on the stock. Finally, Stifel Nicolaus restated a “buy” rating and issued a GBX 950 price target on shares of Oxford Biomedica in a report on Wednesday, March 11th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Oxford Biomedica has a consensus rating of “Moderate Buy” and a consensus target price of GBX 687.

Oxford Biomedica Stock Down 1.5%

The firm has a market cap of £784.76 million, a P/E ratio of -24.11 and a beta of 1.10. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 116.74. The firm has a fifty day moving average of GBX 610.03 and a 200-day moving average of GBX 664.76.

Oxford Biomedica (LON:OXB) last released its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. On average, equities research analysts anticipate that Oxford Biomedica plc will post -31.0799998 earnings per share for the current year.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.